Telomeres — a marker of cell division and lifespan — were found to be shorter in young adults with Prader-Willi…
Patricia Inácio, PhD
Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Patricia Inácio, PhD
Treatment with growth hormone for eight years led to a lower spine curvature in children with Prader-Willi syndrome (PWS) who…
The gut microbiome — the microbial community in the gut — of people with Prader-Willi syndrome (PWS) is more diverse…
Newborns with Prader-Willi syndrome often have a lower birth weight and can be shorter than newborns who do not have…
Saniona will continue to develop Tesomet (tesofensine/metoprolol) as a potential therapy for Prader-Willi syndrome (PWS), with results from a…
Inhibiting an enzyme involved in Prader Willi syndrome (PWS) can help rescue the activity of specific genes in neurons,…
Growth hormone treatment in children younger than 2 with Prader-Willi syndrome (PWS) is safe, reduces body fat, and is linked…
Pitolisant, an investigational anti-sleepiness therapy in the U.S., may help reduce daytime sleepiness and improve cognitive function in children with…
A research project aiming to uncover whether awakening “sleeping” genes could overcome the genetic errors underlying Prader-Willi syndrome (PWS) and…
Soleno Therapeutics Presents Positive Data on DCCR, its Candidate Therapy for Prader-Willi Syndrome
Soleno Therapeutics presented data supporting the clinical benefits of its treatment candidate diazoxide choline controlled-release (DCCR) in patients with Prader-Willi…